LRRC29

Across TCGA pan-cancer cohorts, LRRC29 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of LRRC29’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LRRC29 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LRRC29 is over-expressed in tumor, although a few such as UCEC and BRCA show the opposite, repressed pattern.

KIRC, UCEC, and COAD are the cancer types where LRRC29 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LRRC29 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	III,IV	+0.722	<.001	11	view →
UCEC	All	All	−0.834	<.001	6	view →
COAD	All	All	+0.321	.001	5	view →
BRCA	Female	II,III,IV	−0.421	<.001	4	view →
THCA	Female	All	+0.395	<.001	4	view →
LIHC	Male	All	+0.384	<.001	4	view →
LUAD	All	All	−0.217	.007	4	view →
LUSC	All	All	−0.263	.003	2	view →
CHOL	All	All	+0.481	.014	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

LRRC29–KIRC

Open the KIRC breakdown →